Webinar – Novel Pharmacological Treatments for the Prevention of Cardiovascular Events

Live Webinar

Novel Pharmacological Treatments for the Prevention of Cardiovascular Events

Which agents to use and which patients benefit from the newer interventions?

9^th November 2021 <> 16:30 – 19:00 GMT

Organised and Endorsed by

Supported by an unrestricted educational grant from

Overview

This webinar focuses on the use of novel pharmacological treatment strategies aimed at improving cardiovascular outcomes in medium to high-risk patients. The focus will be on newer lipid lowering agents and novel antidiabetic drugs as well as on gaining insight into newer markers of cardiovascular risk, such as high Lp(a). DOACs and antiplatelet agents will be also discussed in the context of cardiovascular events prevention. The aim of the programme is to increase awareness as to the new advances in lipid lowering treatment and identify those patient subgroups who should benefit the most from these new therapies. The programme will be practical, clinically driven, informative and interactive and of interest to a range of healthcare professionals.

LEARNING OBJECTIVES

> To gain insight into newly emerging agents for the management of dyslipidaemia.
> To understand the role of Lpa in risk stratification.
> To discuss the use and indications of novel anti-diabetic agents for the prevention of cardiovascular events in patients with or without diabetes and CKD patients

AUDIENCE

This webinar is aimed at Cardiologists, General Medicine physicians, kidney specialists, lipid specialists, diabetologists, GPs, trainees in Cardiology, General Medicine and Nephrology as well as nurses and other healthcare professionals with an interest in cardiovascular disease prevention.

FACULTY

Prof Juan Carlos Kaski

Programme Director

Professor of Cardiovascular Science (Emeritus), St George’s, University of London, UK & Hon. Consultant Cardiologist, Cardiology Clinical Academic Group, St. George’s University Hospitals NHS Trust.

Prof Kausik Ray

Co-Chair, Speaker & Panel Discussant

Professor of Public Heath, Department of Public Health and Primary Care, Imperial College London & Honorary Consultant Cardiologist, Imperial College NHS Trust

Prof Heinz Drexel

Co-Chair, Speaker & Panel Discussant

Head of the Department of Internal Medicine & Intensive Care, County Hospital Bregenz, Austria, CEO and Scientific Programme Director, VIVIT Institute, Feldkirch, Austria, Dean of the Medical and Scientific Faculty at Private University of the Principality of Liechtenstein

Prof Ramzi Ajjan

Speaker & Panel Discussant

Professor of Metabolic Medicine & Consultant in Diabetes and Endocrinology, University of Leeds and Leeds Teaching Hospitals NHS Trust

Dr Debasish Banerjee

Speaker & Panel Discussant

Consultant Nephrologist, Care Group Lead, Clinical Sub dean, St George’s University Hospital NHS Foundation Trust & Reader, St George’s, University of London, UK

AGENDA

Chairs: Prof Kausik Ray and Prof Heinz Drexel

Reducing “residual” risk – Lower is better – The ESC guidelines on the management of hyperlipidaemia and beyond. Newer strategies to improve outcomes in patients with diabetes.

All Faculty

AUSPICES, ENDORSEMENTS & DISCLAIMERS

This educational programme has been devised exclusively and independently by its scientific committee and is organised in collaboration with St George’s, University of London (SGUL) and endorsed by the International Society of Cardiovascular Pharmacotherapy (ISCP).

The programme is also supported by Novartis UK who has provided an unrestricted educational grant to partially cover organisational costs and has had no input into the agenda or content of this educational activity.

Save your spot right now

Days

Hours

Minutes

Seconds